Greg Hunt: More time for review if stakeholders make the case

"The timeline for the review raises serious questions about the Government's commitment to reform," says shadow health minister Chris Bowen.

PBAC chair Professor Andrew Wilson was the first to call for a review. He argued for the review in response to concerns over a 'piecemeal' approach to policy. A 'piecemeal' approach to the review hardly seems an appropriate response.

Guild national president George Tambassis has issued a strongly-worded call to action over key issues impacting negotiation of the Seventh Community Pharmacy Agreement.

A number of life sciences companies have been named amongst the list of 119 companies in Australia for gender equality.

Further expansion for consultancy Biointelect with the company opening a Melbourne office and adding additional expertise.

The proposed timeline means it would be shorter than the recent review of NPS MedicineWise and it does not even compare to the reviews of Pharmacy Remuneration and Regulation and Medicines and Medical Devices Regulation.

When it comes to the National Medicines Policy review, the industry must advocate for an approach that starts from first principles - properly assess the performance of the current document and be prepared to set aside what was established in the 1990s.

Specialised Therapeutics Australia says it is "dismayed and frustrated" over the sixth rejection of the Oncotype DX breast cancer tumour profiling test.

Former PBAC chair Emeritus Professor Lloyd Sansom AO presented at the first meeting of the stakeholder group formed to support the government's review of the National Medicines Policy.

New Co-Chairs of the Pharma Australia Inclusion Group with additional companies also joining to take the number of members to 24.

Medidata's Alicia Staley has over 20 years of experience in software design and information systems management. She is also a three-time cancer survivor. Over the past ten years, she has applied her engineering background to improve the patient experience for those dealing with cancer, and shares her thoughts on the future of clinical trials.

"It is critically important that the 7th CPA provides the industry with a framework for continued investment in the industry which represents a critical piece of infrastructure to Australia’s health system," said EBOS CEO John Cullity.